TY - JOUR
T1 - Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion
AU - Han, Jing Yan
AU - Fan, Jing Yu
AU - Horie, Yoshinori
AU - Miura, Soichiro
AU - Cui, De Hua
AU - Ishii, Hiromasa
AU - Hibi, Toshifumi
AU - Tsuneki, Hiroshi
AU - Kimura, Ikuko
N1 - Funding Information:
This work was supported in part by the International Science and Technology Cooperation Project from the Ministry of Science and Technology of the People's Republic of China (2006DFA32340). We would like to thank Ms. Gou Jun, Ms. Li Dan, Mr. Han Dong, and Dr. Man Xu for help in reference collection.
PY - 2008/2
Y1 - 2008/2
N2 - Ischemia and reperfusion (I/R) exerts multiple insults in microcirculation, frequently accompanied by endothelial cell injury, enhanced adhesion of leukocytes, macromolecular efflux, production of oxygen free radicals, and mast cell degranulation. Since the microcirculatory disturbance results in injury of organ involved, protection of organ after I/R is of great importance in clinic. Salvia miltiorrhiza root has long been used in Asian countries for clinical treatment of various microcirculatory disturbance-related diseases. This herbal drug contains many active water-soluble compounds, including protocatechuic aldehyde (PAl), 3,4-dihydroxyphenyl lactic acid (DLA) and salvianolic acid B (SalB). These compounds, as well as water-soluble fraction of S. miltiorrhiza root extract (SMRE), have an ability to scavenge peroxides and are able to inhibit the expression of adhesion molecules in vascular endothelium and leukocytes. Moreover, lipophilic compounds of SMRE also prevent the development of vascular damage; NADPH oxidase and platelet aggregation are inhibited by tanshinone IIA and tanshinone IIB, respectively, and the mast cell degranulation is blunted by cryptotanshinone and 15,16-dihydrotanshinone I. Thus, the water-soluble and lipophilic compounds of SMRE appear to improve the I/R-induced vascular damage multifactorially and synergically. This review will summarize the ameliorating effect of compounds derived from SMRE on microcirculatory disturbance and target organ injury after I/R and will provide a new perspective on remedy with multiple drugs.
AB - Ischemia and reperfusion (I/R) exerts multiple insults in microcirculation, frequently accompanied by endothelial cell injury, enhanced adhesion of leukocytes, macromolecular efflux, production of oxygen free radicals, and mast cell degranulation. Since the microcirculatory disturbance results in injury of organ involved, protection of organ after I/R is of great importance in clinic. Salvia miltiorrhiza root has long been used in Asian countries for clinical treatment of various microcirculatory disturbance-related diseases. This herbal drug contains many active water-soluble compounds, including protocatechuic aldehyde (PAl), 3,4-dihydroxyphenyl lactic acid (DLA) and salvianolic acid B (SalB). These compounds, as well as water-soluble fraction of S. miltiorrhiza root extract (SMRE), have an ability to scavenge peroxides and are able to inhibit the expression of adhesion molecules in vascular endothelium and leukocytes. Moreover, lipophilic compounds of SMRE also prevent the development of vascular damage; NADPH oxidase and platelet aggregation are inhibited by tanshinone IIA and tanshinone IIB, respectively, and the mast cell degranulation is blunted by cryptotanshinone and 15,16-dihydrotanshinone I. Thus, the water-soluble and lipophilic compounds of SMRE appear to improve the I/R-induced vascular damage multifactorially and synergically. This review will summarize the ameliorating effect of compounds derived from SMRE on microcirculatory disturbance and target organ injury after I/R and will provide a new perspective on remedy with multiple drugs.
KW - Adhesion molecules
KW - Antioxidation
KW - Ischemia and reperfusion
KW - Mast cell degranulation
KW - Organ injury
KW - Platelet aggregation
KW - Salvia miltiorrhiza root extract
UR - http://www.scopus.com/inward/record.url?scp=38349123913&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2007.09.008
DO - 10.1016/j.pharmthera.2007.09.008
M3 - 総説
C2 - 18048101
AN - SCOPUS:38349123913
SN - 0163-7258
VL - 117
SP - 280
EP - 295
JO - Pharmacology and Therapeutics
JF - Pharmacology and Therapeutics
IS - 2
ER -